GFM
BPMC

GF Fund Management’s Blueprint Medicines BPMC Stock Holding History

GF Fund Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,626
Closed -$208K – 638
2025
Q2 		$208K Hold
1,626
– – ﹤0.01% 316
2025
Q1 		$144K Buy
1,626
+292
+22% +$28.5K ﹤0.01% 342
2024
Q4 		$116K Buy
+1,334
New +$122K ﹤0.01% 320

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GF Fund Management's BPMC Position: Q3 2025 in Review

GF Fund Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,626 shares — an estimated $208K sold.

GF Fund Management first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $208K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • GF Fund Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • GF Fund Management sold 1,626 Blueprint Medicines shares in Q3 2025, an estimated $208K.
  • GF Fund Management first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
  • GF Fund Management's Blueprint Medicines position peaked at $208K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on GF Fund Management's 13F filing for Q3 2025, filed 7 Nov 2025.